中文 | English
Return
Total: 31 , 1/4
Show Home Prev Next End page: GO
Author:( Peiquan ZHAO)

1.Treatment of experimental anterior chamber fibrin formation with tissue plasminogen activator(t-PA)

Peiquan ZHAO

Ophthalmology in China 1993;0(04):-

2.High myopia-related macular lesions: diagnosis and treatment

Peiquan ZHAO ; Yu XU

Chinese Journal of Ocular Fundus Diseases 2009;25(5):327-330

3.The inhibitory effect of Bevacizumab on retinal neovascularization in oxygen-induced retinopathy in the mouse

Fei FENG ; Peiquan ZHAO

Chinese Journal of Ocular Fundus Diseases 2008;24(3):184-188

4.Evaluation of effect and influence factors of vitrectomy for advanced retinopathy of prematurity

Jiakai LI ; Peiquan ZHAO

Chinese Journal of Ocular Fundus Diseases 2012;28(1):22-25

5.Screening and treatment of retinopathy of prematurity: current status, problems and prospects in China

Peiquan ZHAO ; Ping FEI

Chinese Journal of Ocular Fundus Diseases 2012;28(1):3-7

6.Characteristics and diagnostic value of fundus fluorescein angiography for familial exudative vitreoretinopathy

Qi ZHANG ; Peiquan ZHAO

Chinese Journal of Ocular Fundus Diseases 2011;27(3):263-266

7.Characteristics of choroidal neovascularization secondary to pathologic myopia and anti-VEGF therapy

Lina WANG ; Qi ZHANG ; Peiquan ZHAO

Journal of Shanghai Jiaotong University(Medical Science) 2009;29(10):1251-1255

8.Image features of spectral-domain optical coherence tomography of high myopia with retinoschisis

Shiyuan WANG ; Qing PENG ; Peiquan ZHAO

Chinese Journal of Ocular Fundus Diseases 2011;27(2):132-135

9.Bevacizumab(Avastin) inhibits corneal neovascularization in rabbits

Yuqun ZHANG ; Qing PENG ; Peiquan ZHAO

Academic Journal of Second Military Medical University 2000;0(08):-

10.The status and progress of lamellar hole-associated epiretinal proliferation

Xin LI ; Qi ZHANG ; Peiquan ZHAO

Chinese Journal of Ocular Fundus Diseases 2016;32(5):547-549

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 31 , 1/4 Show Home Prev Next End page: GO